Background: Sickle cell trait and sickle cell disease are thought to be independent risk factors for CKD, but the trajectory and predictors of kidney function decline in patients with these phenotypes are not well understood.

Methods: Our multicenter, observational study used registry data (collected January 2005 through June 2018) and included adult black patients with sickle cell trait or disease (exposures) or normal hemoglobin phenotype (reference) status (ascertained by electrophoresis) and at least 1 year of follow-up and three eGFR values. We used linear mixed models to evaluate the difference in the mean change in eGFR per year.

Results: We identified 1251 patients with sickle cell trait, 230 with sickle cell disease, and 8729 reference patients, with a median follow-up of 8 years. After adjustment, eGFR declined significantly faster in patients with sickle cell trait or sickle cell disease compared with reference patients; it also declined significantly faster in patients with sickle cell disease than in patients with sickle cell trait. Male sex, diabetes mellitus, and baseline eGFR ≥90 ml/min per 1.73 m were associated with faster eGFR decline for both phenotypes. In sickle cell trait, low hemoglobin S and elevated hemoglobin A were associated with faster eGFR decline, but elevated hemoglobins F and A were renoprotective.

Conclusions: Sickle cell trait and disease are associated with faster eGFR decline in black patients, with faster decline in sickle cell disease. Low hemoglobin S was associated with faster eGFR decline in sickle cell trait but may be confounded by concurrent hemoglobinopathies. Prospective and mechanistic studies are needed to develop best practices to attenuate eGFR decline in such patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003305PMC
http://dx.doi.org/10.1681/ASN.2019050502DOI Listing

Publication Analysis

Top Keywords

sickle cell
60
cell trait
36
patients sickle
24
cell disease
24
egfr decline
20
associated faster
16
faster egfr
16
sickle
15
cell
15
black patients
12

Similar Publications

In this cross-sectional study, we examined the contributions of social support in mitigating the burden that sickle cell disease (SCD) has on the well-being of patients living with the condition. SCD patients ( = 139) in Nigeria completed measures of sickle cell distress, social support, and quality of life. Although we found that SCD distress was strongly associated with poorer quality of life, across domains; social support did not mitigate the impact that SCD distress had on the quality of life of patients.

View Article and Find Full Text PDF

Plasma inflammatory and angiogenic protein profiling of patients with sickle cell disease.

Br J Haematol

January 2025

Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam, the Netherlands.

In this study, we aimed to explore the inflammatory and angiogenic pathways in sickle cell disease (SCD). We used proximity extension assay technology (Olink) to measure 92 plasma proteins involved in inflammation and angiogenesis. Plasma samples were collected from 57 SCD patients (sickle cell anaemia/HbS-β thalassaemia-thalassaemia) in steady-state and 13 healthy ethnicity-matched healthy controls (HCs).

View Article and Find Full Text PDF

Purpose: Arabic is the primary language used in the Middle East, where sickle cell disease (SCD) is prevalent. This study aims to quantify Arabic web educational materials for patients with SCD and provide a descriptive standardized assessment.

Methods And Materials: This retrospective, descriptive study aimed to analyze Arabic websites on SCD through the Discern instrument and JAMA benchmark.

View Article and Find Full Text PDF

Purpose: Tanzania is the fifth country with the highest sickle cell disease (SCD) prevalence globally. Although hydroxyurea (HU) is available, only 25% of persons with SCD are reported to use it in Tanzania. Perceived disease threat is associated with medication usage in patients with chronic diseases.

View Article and Find Full Text PDF

Current and Emerging Approaches Targeting G9a for the Treatment of Various Diseases.

J Med Chem

December 2024

Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Center and Laboratory of Neuro-system and Multimorbidity, Core Facilities, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

G9a, a histone lysine methyltransferase, is instrumental in regulating gene expression through epigenetic modifications. Its overexpression is closely linked to the progression of various human diseases, including cancers. Therefore, targeting G9a enzyme is a promising strategy for treating various diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!